A voluntary rebate pilot for the 340B drug discount program is drawing attention as a potential way to address concerns over ...

Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), ...

Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. Product revenue ...

Texas, USA-based clinical-stage biotech Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies ...

A San Francisco–based biotech company developing precision medicines through an integrated discovery platform that combines ...

US pharma major AbbVie yesterday announced a $195 million investment in its North Chicago, Illinois manufacturing plant to ...

UK-based contract research development and manufacturing organization (CRDMO) Arcinova, a subsidiary of Quotient Sciences, ...

Evotec SE (XETRA: EVT) reported second-quarter 2025 revenues of $188 million, down 6% year-on-year, as strength in its biologics division partly offset weaker demand in discovery and preclinical ...

The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...

With the threat of US tariffs on pharmaceuticals looming in the coming weeks, Morningstar DBRS has taken a closer look at ...

An Expert View from Lindsay Mateo, chief commercial officer at Weave Bio.

Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and ...